Non-respiratory symptoms including poor sleep, fatigue, pain, anxiety, and depressive symptoms were prevalent among adults with cystic fibrosis (AwCF) and persisted after 1 year of follow-up, based on ...

Evolution in the management of cystic fibrosis has led to more patients surviving to adulthood, but data on the trends and comorbidities in adult patients, and the impact of disparities in access to ...

This study update could positively impact Vertex Pharmaceuticals and Moderna’s stock performance, as successful results may enhance their competitive position in the cystic fibrosis treatment market.

Please provide your email address to receive an email when new articles are posted on . The study reported elevated adjusted rates for four non-pulmonary complications in those with vs. without cystic ...

Arcturus Therapeutics (($ARCT)) announced an update on their ongoing clinical study. Study Overview: Arcturus Therapeutics is conducting a Phase 2 ...

Extra mucus in the digestive tracts of people with CF causes stool to move more slowly and slows the production of enzymes, causing blockages and constipation. Laxatives can often help, but severe ...

In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA ...

To topple access barriers to Vertex Pharmaceuticals’ potentially lifesaving, yet often out-of-reach cystic fibrosis therapy ...